Project Grant HT94252410060
Award Date 4/1/24
Completion Date 3/31/27
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,619,668 project grant to The University of Texas MD Anderson Cancer Center to inhibit brain metastases of HER2/neu-positive breast cancers using extracellular vesicles from renovated dendritic cells. The award began on May 1, 2024 and is scheduled for completion on April 30, 2027. The project aims to develop innovative treatments to improve outcomes for military service members and the...
- The U.S. Defense Health Agency has awarded a $7,001,734 Project Grant to The University of Texas MD Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The grant, which runs from August 15, 2024 to August 14, 2028, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to drive innovative cancer research and explore new approaches to prevention, diagnosis,...
- This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
- The federal Project Grant award, with ID HT94252410992, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, totaling $2,710,479.00, will fund a research initiative led by the University of Texas M.D. Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The award's performance period is from August 15, 2024 to...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $5.47M project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) beginning September 1, 2025 and concluding August 31, 2029. The award funds research targeting ganglioside GD2 to overcome chemotherapy resistance in triple-negative breast cancer. This research initiative aims to develop novel therapeutic approaches to address drug resistance...
- The federal Project Grant award of $735,799.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant is awarded to the University of Texas MD Anderson Cancer Center to support the project "INNOVATING BREAST CANCER RNA THERAPY: MECHANISMS AND PHARMACOGENETIC INHIBITORS". The project aims to conduct advanced biomedical research focused on transforming healthcare for military service members and the broader public,...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $414,472 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award supports research focused on targeting neuronal mimicry in SMARCB1 (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin, subfamily B, member 1)-deficient renal medullary...
- This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,444,922.00 to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct research on a novel epigenetic determinant in metastatic prostate cancer. The award period is from September 15, 2024 to September 14, 2027. MD Anderson, a comprehensive cancer research and treatment center, will utilize this funding to carry out basic,...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $1.14M Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. The award funds research targeting the PRMT3-IGF2BP1 axis-mediated epitranscriptomic reprogramming as a novel therapeutic strategy to overcome immunotherapy resistance in clear cell renal cell carcinoma (ccRCC). This research...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $559,576 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 1, 2026, through June 30, 2029. The award funds research investigating desmoplastic small round cell tumors (DSRCTs), with a focus on understanding plasticity and resistance mechanisms to improve therapeutic outcomes. This research addresses a critical gap...